PMID: 9419352Feb 21, 1998Paper

Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage

Proceedings of the National Academy of Sciences of the United States of America
L ChenJ Chen

Abstract

The MDM2 oncogene encodes an inhibitor of the p53 tumor suppressor protein that regulates p53 in a negative feedback loop. MDM2 gene amplification and overexpression occur in several types of tumors and are often associated with poor prognosis. An MDM2 antisense phosphorothioate oligodeoxynucleotide has been identified that effectively inhibits MDM2 expression in tumor cells containing MDM2 gene amplifications. Antisense inhibition of MDM2 is associated with a decrease in MDM2-p53 complex formation, increase in p53-inducible gene expression, increase in p53 transcriptional activity, and apoptosis. Significantly, inhibition of MDM2 expression enhances the activation of p53 by a DNA-damaging cancer chemotherapy agent in a synergistic fashion. Therefore, the MDM2 negative feedback pathway is an important limiting factor in DNA damage-induced p53 activation. MDM2 antisense oligonucleotides may be useful as antitumor agents alone or as enhancers of other conventional DNA-damaging drugs.

References

Aug 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·S J KuerbitzM B Kastan
Jul 1, 1993·Molecular and Cellular Biology·J ChenA J Levine
Nov 1, 1994·Molecular and Cellular Biology·V MarechalA J Levine
Sep 1, 1994·Nucleic Acids Research·A Bairoch
Nov 4, 1994·Science·S W LoweT Jacks
Apr 1, 1994·Molecular and Cellular Biology·C E DabrowskiP A Schaffer
Mar 29, 1994·Proceedings of the National Academy of Sciences of the United States of America·C Y ChenM B Kastan
Nov 19, 1993·Cell·W S el-DeiryB Vogelstein
Jul 1, 1993·Genes & Development·X WuA J Levine
May 15, 1993·Cancer·A T MeadowsS L Lozowski
May 1, 1996·Molecular and Cellular Biology·J ChenA J Levine
Jan 1, 1996·Breast Cancer Research and Treatment·C E Bueso-RamosM Albitar
Sep 1, 1996·Molecular and Cellular Biology·T A FiddlerM J Thayer
May 15, 1997·Nature·Y HauptM Oren
May 15, 1997·Nature·M H KubbutatK H Vousden
Jun 13, 1997·The Journal of Biological Chemistry·P ErhardtG M Cooper
Sep 5, 1997·The Journal of Biological Chemistry·L ChenJ Chen

❮ Previous
Next ❯

Citations

May 2, 2003·Archives of Pharmacal Research·Yoon S Cho-Chung
Mar 16, 2007·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Limin LiuYongrong Mao
Mar 13, 2013·Bioorganic & Medicinal Chemistry·Pradip GhoshKing Li
Sep 24, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·W Jongmans, J Hall
Feb 5, 2000·Bioorganic & Medicinal Chemistry·Z JiangS Agrawal
Feb 1, 2000·Molecular Medicine Today·S Agrawal, E R Kandimalla
Sep 16, 1998·Current Opinion in Chemical Biology·S Agrawal, Q Zhao
Nov 4, 2000·The Biochemical Journal·T R HuppK L Ball
Mar 22, 2000·Antisense & Nucleic Acid Drug Development·M TraidejJ Chen
Jul 22, 1998·Nucleic Acids Research·J MomandJ Niland
Jan 2, 2003·Molecular and Cellular Biology·Susan M MendrysaMary Ellen Perry
Aug 19, 2005·Molecular and Cellular Biology·Guilian NiuHua Yu
Jul 23, 2011·Genes & Cancer·Susan M MendrysaReem Malek
Sep 28, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Ute FischerKlaus Schulze-Osthoff
Dec 13, 2005·American Journal of Pharmacogenomics : Genomics-related Research in Drug Development and Clinical Practice·Zhuo ZhangHui Wang
Sep 18, 2003·Proceedings of the National Academy of Sciences of the United States of America·Zhuo ZhangRuiwen Zhang
Oct 31, 2002·Proceedings of the National Academy of Sciences of the United States of America·Zhihong LaiRobert A Copeland
Apr 24, 2014·Apoptosis : an International Journal on Programmed Cell Death·Xin YuDarren R Carpizo
Jun 25, 2003·Proceedings of the National Academy of Sciences of the United States of America·Leonard GirnitaOlle Larsson
Nov 10, 2009·Seminars in Cancer Biology·Nerea Allende-Vega, Mark K Saville
May 28, 2008·Life Sciences·Madhusudhanan NarasimhanAppu Rathinavelu
Nov 28, 2006·Trends in Molecular Medicine·Lyubomir T Vassilev
Oct 13, 2012·Medicinal Research Reviews·Weisi Wang, Yongzhou Hu
Jun 19, 2012·Chemical Biology & Drug Design·Wayne A WarnerJamil Momand
Oct 22, 2005·Cancer Letters·Roberta PangRonnie T P Poon
Feb 22, 2012·Neuroscience Letters·Sara Ghassemifar, Susan M Mendrysa
Jul 27, 1999·Current Opinion in Chemical Biology·J K Buolamwini
Aug 11, 2001·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Ute M. Moll, Alex Zaika

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis